A Aralex Aachen research explorer

Unit Janssen (Netherlands)

Janssen Sign in to save

6 authors · 15 authorships · All papers →

People 6

6 results

Papers 14

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
2021 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access cited by 2 patents

104

citations
2022 White Paper on Recent Issues in Bioanalysis: Enzyme Assay Validation, BAV for Primary End Points, Vaccine Functional Assays, Cytometry in Tissue, LBA in Rare Matrices, Complex NAb Assays, Spectral Cytometry, Endogenous Analytes, Extracellular Vesicles Part 2 – Recommendations on Biomarkers/CDx, Flow Cytometry, Ligand-Binding Assays Development & Validation; Emerging Technologies; Critical Reagents Deep Characterization
2023 Bioanalysis article Immunology and Microbiology Biosimilars and Bioanalytical Methods

16

citations
P495 Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials
2022 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease

16

citations
FRI0362 COMPARATIVE EFFECTIVENESS OF USTEKINUMAB (UST) AND TNF INHIBITORS (TNFI) IN PATIENTS WITH PSORIATIC ARTHRITIS (PSA) IN THE REAL-WORLD, MULTINATIONAL PSABIO STUDY: 12-MONTH FOLLOW-UP
2020 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments

14

citations
Accelerating Global Deletion of the Abnormal Toxicity Test for vaccines and biologicals. Planning common next steps. A workshop Report
2022 Biologicals article Veterinary Animal testing and alternatives Open access

12

citations
Harmonization of Vaccine Ligand Binding Assays Validation
2024 Bioanalysis article Immunology and Microbiology Biosimilars and Bioanalytical Methods Open access

10

citations
2024 White paper on recent issues in bioanalysis: Impact of LDT in US and IVDR in EU; AI/ML for High Parameter Flow Cytometry; The rise of Olink Technology; CDx for AAV Gene Therapies; Integrative Bioanalysis by Multiple Platforms; Super Sensitive ADA/NAb LBA ( PART 2A – Recommendations on Advanced Strategies for Biomarkers, IVD/CDx Assays (BAV), Cell Based Assays (CBA), and Ligand-Binding Assays (LBA) PART 2B – Regulatory Agencies’ Input on Biomarkers, IVD/CDx, and Biomarker Assay Validation)
2025 Bioanalysis article Immunology and Microbiology Biosimilars and Bioanalytical Methods Open access

4

citations
OP0230 EFFICACY AND SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO DEMONSTRATED INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR INHIBITION: WEEK 24 RESULTS OF A PHASE 3B, RANDOMIZED, CONTROLLED STUDY
2021 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

4

citations
SAT0432 EFFECT OF SEX ON DISEASE CHARACTERISTICS AND DISEASE IMPACT IN PATIENTS WITH PSORIATIC ARTHRITIS (PsA): INSIGHTS FROM THE REAL-WORLD, OBSERVATIONAL MULTINATIONAL PsABio COHORT
2020 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access

2

citations
SAT0398 PERSISTENCE OF USTEKINUMAB (UST) OR TNF INHIBITOR (TNFI) TREATMENT IN PSORIATIC ARTHRITIS (PsA): INSIGHTS FROM THE LARGE, PROSPECTIVE, MULTINATIONAL, REAL-WORLD PsABio COHORT
2020 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access

2

citations
POS1043 STRONG CORRELATION BETWEEN SHORT- VS LONG-FORM COMPOSITE MEASURES OF PSORIATIC ARTHRITIS DISEASE ACTIVITY IN A TNFi-IR POPULATION TREATED WITH GUSELKUMAB: DATA FROM THE PHASE 3b COSMOS TRIAL
2022 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

2

citations
AB0898 Guselkumab improves dactylitis in PsA patients with inadequate response to TNFi: data from the Phase 3b COSMOS trial
2022 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

0

citations
POS1015 SAFETY OF GUSELKUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO ARE BIO-NAÏVE OR TNFi-EXPERIENCED: POOLED RESULTS FROM 4 RANDOMIZED CLINICAL TRIALS THROUGH 2 YEARS
2022 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

0

citations
POS1038 GUSELKUMAB EFFICACY IN PSORIATIC ARTHRITIS ASSESSED BY MULTI-DOMAIN COMPOSITE INDICES: DATA FROM THE PHASE 3B COSMOS TRIAL IN A TNFi-IR POPULATION
2022 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access

0

citations

14 results